Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 311

 

Home  | About Us | Editors | Search | Ahead Of Print | Current Issue | Archives | Submit Article | Instructions | Subscribe | Contacts | Login 
     
ORIGINAL ARTICLE
Year : 2018  |  Volume : 8  |  Issue : 1  |  Page : 36-40

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding


1 Department of Pharmacy, IU Health Methodist Hospital, Indianapolis, IN, USA
2 Department of Pharmacy, Via Christi Hospitals, Wichita, KS, USA
3 Department of Pharmacy, Grady Health System, Atlanta, GA, USA
4 Department of Pharmacy, Fletcher Allen Health Care, Burlington, VT, USA
5 Department of Pharmacy, Eskenazi Health, Indianapolis, IN, USA
6 Department of Pharmacy, Bronson Methodist Hospital, Kalamazoo, MI, USA

Correspondence Address:
Dr. Tara Holt
Department of Pharmacy, IU Health Methodist Hospital, 1701 N. Senate Blvd, AG 401, Indianapolis, IN 46202
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJCIIS.IJCIIS_40_17

Rights and Permissions

Objective: The objective of this study was to evaluate the effectiveness of 3-factor prothrombin complex concentrate (3F-PCC) compared to 4-factor PCC (4F-PCC) in warfarin-associated bleeding. Methods: This multicenter, retrospective, cohort study analyzed data from patients admitted between May 2011 and October 2014 who received PCC for warfarin-associated bleeding. The primary outcome was the rate of international normalized ratio (INR) normalization, defined as an INR ≤1.3, after administration of 3F-PCC compared to 4F-PCC. Other variables of interest included the incidence of additional reversal agents, new thromboembolic events, and mortality. Results: A total of 134 patients were included in the analysis. The average dose of PCC administered was 24.6 ± 9.3 units/kg versus 36.3 ± 12.8 units/kg in the 3F-PCC and 4F-PCC groups, respectively, P < 0.001. Baseline INR in the 3F-PCC and 4F-PCC groups was 3.61 ± 2.3 and 6.87 ± 2.3, respectively P < 0.001. 4F-PCC had a higher rate of INR normalization at first INR check post-PCC administration compared to 3F-PCC (84.2% vs. 51.9%, P = 0.0001). Thromboembolic events, intensive care unit and hospital length of stay, and mortality were similar among both groups. Conclusion: The use of 4F-PCC leads to a more significant reduction in INR compared to 3F-PCC though no difference in mortality or length of stay was observed. Thromboembolism rates were similar among both groups.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2005    
    Printed45    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    
    Cited by others 3    

Recommend this journal